Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd

SSE:603707.SS

11.31 (CNY) • At close June 13, 2025
Overview | Financials

Numbers are in millions (except for per share data and ratios) CNY.

2025 Q12024 Q42024 Q32024 Q22024 Q12023 Q42023 Q32023 Q22023 Q12022 Q42022 Q32022 Q22022 Q12021 Q42021 Q32021 Q22021 Q12020 Q42020 Q32020 Q22020 Q12019 Q42019 Q32019 Q22019 Q12018 Q42018 Q32018 Q22018 Q12017 Q42017 Q32017 Q22017 Q12016 Q42016 Q32016 Q22016 Q1
Revenue 885.219835.577945.351,132.9751,000.337766.593838.185996.251,307.483861.722875.675798.7631,176.561906.5961,028.803868.242883.053756.511762.549661.669734.152641.706651.436566.534609.994395.938454.572414.18435.641328.799300.107260.18223.64130.729143.34169.824138.02
Cost of Revenue 580.612419.049528.773679.588617.685462.712432.627512.261644.978411.925419.201354.388582.484400.961450.284370.152374.725319.816321.713229.618325.118305.265311.718267.11320.237188.467227.767204.924238.081174.559149.554149.668122.90376.37884.78972.381103.673
Gross Profit 304.607416.528416.577453.387382.652303.88405.558483.989662.504449.797456.474444.375594.077505.635578.519498.089508.328436.695440.836432.051409.034336.441339.717299.424289.757207.471226.805209.255197.559154.24150.553110.512100.73754.35158.55197.44434.347
Gross Profit Ratio 0.3440.4980.4410.40.3830.3960.4840.4860.5070.5220.5210.5560.5050.5580.5620.5740.5760.5770.5780.6530.5570.5240.5210.5290.4750.5240.4990.5050.4530.4690.5020.4250.450.4160.4080.5740.249
Reseach & Development Expenses 69.243113.69441.8986.34974.904144.45461.99283.16667.645102.14255.65952.40153.4667.6957.47761.87733.91143.40348.84647.58647.69844.63146.82238.52336.37316.24433.97526.35824.606110.65214.82828.89049.048024.9370
General & Administrative Expenses 42.608-62.3790.814-8.99939.414-60.86678.806-6.10332.551-39.79677.264-5.63831.289-29.55750.587-7.07427.05-41.7617.394-17.67141.853-8.6489.002-2.0727.945-16.3088.197-29.71135.454-66.59524.732-19.99428.976-70.39237.54741.6660
Selling & Marketing Expenses 83.78786.30550.95177.5665.189111.85447.163140.705120.85101.184135.078113.568101.887115.021140.872107.188120.736108.199137.763124.2475.99390.29799.56299.47368.944103.50360.97253.00730.20223.87415.684.2573.1572.8962.3314.7280
SG&A 126.39523.935141.765126.02107.831141.808125.97134.602153.40261.388212.343107.93133.17685.463191.459100.114147.78666.438155.158106.569117.84681.649108.56497.40176.88987.19469.16923.29665.656-42.72140.413-15.73632.133-67.49639.87847.0970
Other Expenses 16.227-6.185-16.564-1.8211.731-1,243.5284.70111.11513.573109.864-33.43548.3058.81814.003-3.1894.06210.19112.10120.8863.4581.2055.0111.0271.4885.1993.8361.6391.3370.4751.8640.6940.6630.4541.8532.066-110.839-103.673
Operating Expenses 211.865131.444167.091212.369182.7351,529.79155.345269.5234.619273.393234.567208.637195.454249.588228.461188.144182.805178.332205.186192.434166.445171.106156.361148.022114.126129.97104.07389.60366.64567.71741.26431.86232.90811.30239.88-110.839-103.673
Operating Income 92.743285.085249.486241.017199.917-1,225.91215.945343.617379.461120.563331.585333.309388.094217.559339.885321.169303.32204.968214.564223.223234.227168.715177.752151.727169.44882.769119.081118.414140.16889.391117.63878.25267.16147.68720.05758.98534.347
Operating Income Ratio 0.1050.3410.2640.2130.2-1.5990.2580.3450.290.140.3790.4170.330.240.330.370.3430.2710.2810.3370.3190.2630.2730.2680.2780.2090.2620.2860.3220.2720.3920.3010.30.3650.140.3470.249
Total Other Income Expenses Net -0.0040.002-2.206-1.8211.731-20.8212.75713.0592.21114.7923.006-21.1111.67310.096-10.314.06210.19112.10120.8863.4581.2055.2010.8371.4885.1993.8361.640.8640.5672.0720.5730.6630.4541.7382.012108.4020.38
Income Before Tax 92.739285.086247.279259.174200.494-1,246.73218.702356.677381.672135.355334.592325.655389.767228.315336.696325.231313.511217.069235.449226.681235.432173.725178.779153.215174.64786.605120.72119.751140.64391.462118.21178.91667.61549.42522.068167.38734.727
Income Before Tax Ratio 0.1050.3410.2620.2290.2-1.6260.2610.3580.2920.1570.3820.4080.3310.2520.3270.3750.3550.2870.3090.3430.3210.2710.2740.270.2860.2190.2660.2890.3230.2780.3940.3030.3020.3780.1540.9860.252
Income Tax Expense 8.02864.76346.51931.34623.307-223.0343.88764.4949.344-46.31843.21742.71159.2419.82445.71544.00840.29129.61733.06923.87831.41316.02219.44412.88925.768-3.4813.37314.28318.9940.90417.81911.73811.521-2.9234.341123.761-98.455
Net Income 84.714220.361200.767227.827177.19-1,028.753214.807292.175332.325183.787293.011283.946330.089214.596289.176282.623272.898192.997204.651204.071204.404156.423159.335140.326148.87890.085107.348105.468121.64990.558100.39267.17856.09452.34817.728157.65529.509
Net Income Ratio 0.0960.2640.2120.2010.177-1.3420.2560.2930.2540.2130.3350.3550.2810.2370.2810.3260.3090.2550.2680.3080.2780.2440.2450.2480.2440.2280.2360.2550.2790.2750.3350.2580.2510.40.1240.9280.214
EPS 0.050.1330.120.140.11-0.640.130.180.210.110.240.230.270.130.240.230.220.160.130.170.170.130.10.120.120.0740.0680.0870.0770.0790.0690.0650.0320.0510.0130.150.022
EPS Diluted 0.050.1320.120.140.11-0.640.130.180.20.110.240.230.270.130.240.230.220.160.130.170.170.130.10.120.120.0740.0680.0870.0770.0790.0690.0650.0320.0510.0130.150.022
EBITDA 103.559300.916264.464319.386258.382-1,181.072286.144408.547431.121182.72390.24356.38431.932260.87354.941365.786346.641235.601250.727238.175247.693175.28190.542169.571176.87589.123125.395133.277130.051104.869119.49-76.249223.64173.44618.671-55.044138.02
EBITDA Ratio 0.1170.360.280.2820.258-1.5410.3410.410.330.2120.4460.4460.3670.2880.3450.4210.3930.3110.3290.360.3370.2730.2920.2990.290.2250.2760.3220.2990.3190.398-0.29311.3270.13-0.3241